Although these pathways are believed to induce the proliferation of neurofibroma cells and COL1A1 production, leading to neurofibroma formation, the therapeutic outcomes of the specific mTOR inhibitor sirolimus and the anti-collagenogenic pirfenidone in clinical trials have not been satisfactory21,22. This evidence concerns the gene MTOR and plexiform neurofibroma.